Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Business Restructuring to Bolster R&D, MR Force: Daiichi
May 24, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 24, 2004
- WORLD NEWS IN BRIEF
May 24, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 24, 2004
- MRs Should Be Fair to Provide Drug Info: Mr Tohma of Pfizer
May 24, 2004
- Annual Business Results
May 24, 2004
- Annual Business Results
May 24, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 24, 2004
- 1st Qtr Business Results
May 24, 2004
- Sankyo, Kowa: AII Receptor Blocker Olmetec
May 24, 2004
- Eli Lilly Japan, Chugai: Evista for Postmenopausal Osteoporosis
May 24, 2004
- Kissei, Takeda: Glufast Tab
May 24, 2004
- Novartis: Visudyne for AMD
May 24, 2004
- BUSINESS NEWS IN BRIEF
May 24, 2004
- Janssen's "Spend A Day" MR Support Program Found Effective
May 17, 2004
- The 48th Meeting of the Japan College of Rheumatology
May 17, 2004
- Alfresa Aims to Expand Group Membership in SAFE
May 17, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 17, 2004
- Takeda, Banyu Hired Over 200 New Graduates in April: PJ Survey
May 17, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 17, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…